




The relative strengths and weaknesses of Keenova Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keenova Therapeutics plc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Keenova Therapeutics plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 258%, being 43% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	1,629,100
Cost of Goods Sold	1,152,600
Intangible Assets	419,400
Liabilities, Current	431,400
Liabilities, Non-Current	102,900
Other Assets	863,500
Other Compr. Net Income	2,500
Other Expenses	376,700
Other Liabilities	1,122,500
Other Net Income	19,200
Other Revenues	1,979,700
Property and Equipment	390,600
Research and Development	115,700
Selling, General and Administrative Expense	566,800

Output Variable	Value in 1000 USD
Assets	3,302,600
Liabilities	1,656,800
Expenses	2,211,800
Revenues	1,979,700
Stockholders Equity	1,645,800
Net Income	-212,900
Comprehensive Net Income	-211,650
BaseVar	4,586,300
ECR before LimitedLiability	136%
Economic Capital Ratio	258%